Gene Therapy in Mesotheliomas

Recent Advances in Hemophilia Gene Therapy

Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are ...

ژن درمانی Gene Therapy

Genomic Landscape of Malignant Mesotheliomas.

Understanding the genomic landscape of malignant mesothelioma may identify novel molecular drivers of this ultra-rare disease, which can lead to an expanded roster of targeted therapies and clinical trial options for patients with mesothelioma. We examined the molecular profiles of 42 patients with malignant mesothelioma (including pleural, peritoneal, and pericardial) that were referred by cli...

Mesotheliomas all: long before their time.

Editorial Mesotheliomas all : long before their time In 1935 in the Ulster Medical Journal, Campbell and Young' reported a cluster of three cases of pleural tumour which they had observed in Belfast within five months. They concluded that each was a primary tumour of the pleura and they entitled their paper: "A Primary Tumour (Mixed-Cell Sarcoma) of the Pleura" The case reports are predominantl...

The Role of Gene Therapy in Cartilage Repair

The key principle of gene delivery to articulations by direct intra-articular injection is to release complementary DNA(cDNA)-encoding medical products that will lead to maintained, endogenous production of the gene products withinthe articulation. In fact, this has been accomplished for both in vivo and ex vivo gene delivery, using several vectors,genes, and cells in some animal models. Some c...